PrecISE: Precision Medicine in Severe Asthma: An adaptive platform trial with biomarker ascertainment

Overview of attention for article published in The Journal of Allergy and Clinical Immunology, March 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news: 1 news outlet
blogs: 1 blog
twitter: 11 X users

facebook: 2 Facebook pages
podcasts: 1 podcast

Readers on

mendeley: 51 Mendeley

So far, Altmetric has seen 3 public wall posts from 2 users.

Sociedad Ecuatoriana De Alergia,asma E Inmunologia (SEAAI), 21 May 2021

Severe asthma accounts for almost half the cost associated with asthma. Severe asthma is driven by heterogeneous molecular…

Sociedad Ecuatoriana De Alergia,asma E Inmunologia (SEAAI), 13 May 2021

Severe asthma accounts for almost half the cost associated with asthma. Severe asthma is driven by heterogeneous molecular…

Journal of Allergy and Clinical Immunology, 13 May 2021

The development of therapies for asthma using conventional clinical trial design requires years. On behalf of the NIH Precision…

This page shows the most recent Facebook posts that mention this research output. Click here to find out how to access more activity.